P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents
Bilal Mohty,Jean El-Cheikh,Ibrahim Yakoub-Agha,Hervé Avet-Loiseau,Hervé Avet-Loiseau,Philippe Moreau,M. Mohty +6 more
TL;DR: This review aimed to assess the available research data addressing ‘retreatment’ approaches, drug ‘sequencing’ and the long-term impact of upfront therapy with novel drugs.
Journal ArticleDOI
Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
Arthur R. Bradwell,Stephen Harding,Fourrier N,Claire Mathiot,M. Attal,Philippe Moreau,J L Harousseau,Hervé Avet-Loiseau +7 more
TL;DR: HLC ratios may have a role in clinical management of MM, and no significant associations were observed between PFS and M-spike concentrations, suppression of non-tumor Igs of different isotypes or FLC κ/λ ratios.
Journal ArticleDOI
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Florent Malard,Richard Szydlo,Eolia Brissot,Patrice Chevallier,Thierry Guillaume,Jacques Delaunay,Sameh Ayari,Viviane Dubruille,Steven Le Gouill,Beatrice Mahe,Thomas Gastinne,Nicolas Blin,Beatrice Saulquin,Jean-Luc Harousseau,Philippe Moreau,Mohamad Mohty +15 more
TL;DR: It is concluded that precise monitoring of CsA concentrations and adjustment ofCsA dose early after allo-SCT may be effective to prevent onset of severe aGVHD.
Journal ArticleDOI
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.
David Chiron,Celine Bellanger,Antonin Papin,Benoit Tessoulin,Christelle Dousset,Christelle Dousset,Sophie Maïga,Anne Moreau,Julie Esbelin,Valérie Trichet,Valérie Trichet,Selina Chen-Kiang,Philippe Moreau,Cyrille Touzeau,Steven Le Gouill,Martine Amiot,Catherine Pellat-Deceunynck +16 more
TL;DR: By identifying the microenvironment as the major support for proliferation and drug resistance in MCL, the results highlight a selective approach to target the lymphoma niche and highlight the sensitivity toward venetoclax and alkylating drugs.
Journal ArticleDOI
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Philippe Moreau,Ievgenii Karamanesht,Natalia Domnikova,Maryna Y. Kyselyova,Kateryna Vilchevska,Vadim A Doronin,Alexander Schmidt,Cyrille Hulin,Xavier Leleu,Dixie-Lee Esseltine,Karthik Venkatakrishnan,Donna Skee,Huaibao Feng,Suzette Girgis,Andrew Cakana,Helgi van de Velde,William Deraedt,Thierry Facon +17 more
TL;DR: Findings from a phase III study demonstrated that subcutaneous administration of bortezomib, using the same dose and schedule, resulted in similar efficacy with an improved systemic safety profile versus intravenous bortzomib in patients with relapsed MM.